WO2006016828A3 - Use of alpha ketoglutarate for treating alzheimer, parkinson - Google Patents

Use of alpha ketoglutarate for treating alzheimer, parkinson Download PDF

Info

Publication number
WO2006016828A3
WO2006016828A3 PCT/PL2005/000051 PL2005000051W WO2006016828A3 WO 2006016828 A3 WO2006016828 A3 WO 2006016828A3 PL 2005000051 W PL2005000051 W PL 2005000051W WO 2006016828 A3 WO2006016828 A3 WO 2006016828A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
parkinson
glutarate
keto
apoptosis
Prior art date
Application number
PCT/PL2005/000051
Other languages
French (fr)
Other versions
WO2006016828A8 (en
WO2006016828A2 (en
Inventor
Martyna Kandefer-Szerszen
Wojciech Rezeski
Barbara Zdzisinska
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Martyna Kandefer-Szerszen
Wojciech Rezeski
Barbara Zdzisinska
Stefan Pierzynowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab, Martyna Kandefer-Szerszen, Wojciech Rezeski, Barbara Zdzisinska, Stefan Pierzynowski filed Critical Sgp & Sons Ab
Publication of WO2006016828A2 publication Critical patent/WO2006016828A2/en
Publication of WO2006016828A3 publication Critical patent/WO2006016828A3/en
Publication of WO2006016828A8 publication Critical patent/WO2006016828A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of at least one member selected from the group consisting of alpha-ketoglutarate and its salts: ornithyno-alpha-keto-glutarate, asparagine-alpha-keto-glutarate and other salts with amino acids and salts of alpha-keto-glutarate with metal ions such Na, Ca, Mg, Cu, Sr, Zn, K and others in doses 0.001-1 g/kg/day or in concentration 0.001 mM-100mM for the manufacture of a pharmaceutical preparation and/or food/ feed additive augmenting, supporting the function of the nerve cells and nervous system and simultaneously minimizing, preventing the apoptosis of nerve cells and preventing the development of diseases of nervous system in adolescent, adult and fetuses in mammals, including people, such as Alzheimer, Parkinson, Huntington, Creutzweld-Jakob, BSE and other diseases and protecting the nervous system function against its degeneration due to apoptosis of nerve cells in Alzheimer, Parkinson, Huntington, Creutzweld-Jakob, BSE and other diseases and protecting the growth and stimulating the reproduction and preventing the apoptosis of nerve and other cells in vitro and in biotechnological processes with the use of somatic and bacterial cells .
PCT/PL2005/000051 2004-08-12 2005-08-11 Use of alpha ketoglutarate for treating alzheimer, parkinson WO2006016828A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.369552 2004-08-12
PL369552A PL369552A1 (en) 2004-08-12 2004-08-12 Pharmaceutical or/and nutrient or/and laboratory preparation for increasing, supporting the functioning of nerve cells and nervous system as well as application of pharmaceutical or/and nutrient or/and laboratory preparation in protection of the functions

Publications (3)

Publication Number Publication Date
WO2006016828A2 WO2006016828A2 (en) 2006-02-16
WO2006016828A3 true WO2006016828A3 (en) 2006-06-08
WO2006016828A8 WO2006016828A8 (en) 2007-07-19

Family

ID=35462217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2005/000051 WO2006016828A2 (en) 2004-08-12 2005-08-11 Use of alpha ketoglutarate for treating alzheimer, parkinson

Country Status (2)

Country Link
PL (1) PL369552A1 (en)
WO (1) WO2006016828A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536823B1 (en) 2010-02-18 2017-12-20 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible chorionic membrane products
KR102198633B1 (en) * 2012-09-19 2021-01-05 그레스포 에이비 Compositions for improvement of brain function
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
WO2019038655A1 (en) * 2017-08-21 2019-02-28 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
CN117530940A (en) * 2023-10-11 2024-02-09 四川大学华西第二医院 Application of alpha-ketoglutarate in preparation of medicines for promoting myelin repair and improving neuroinflammation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034301A1 (en) * 1994-06-10 1995-12-21 Pharmacia & Upjohn Ab Energy substrates
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
EP0922459A1 (en) * 1997-12-12 1999-06-16 Ernst-Günter Prof. Dr. Dr. Afting Pharmaceutical compositions comprising D-galactose and the use thereof
WO1999066918A1 (en) * 1998-06-23 1999-12-29 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20020193335A1 (en) * 2001-03-02 2002-12-19 Hesson David P. Gene therapy for neurological tissues
NZ530554A (en) * 2004-01-13 2004-04-30 A Neuronutrients
US20040127413A1 (en) * 2001-03-29 2004-07-01 Thierry Plouvier Enteric keto acid and amino acid salts and their use for preparing medicines
WO2005039539A1 (en) * 2003-10-23 2005-05-06 Medical Research Institute ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE α-KETOGLUTARATE

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034301A1 (en) * 1994-06-10 1995-12-21 Pharmacia & Upjohn Ab Energy substrates
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
EP0922459A1 (en) * 1997-12-12 1999-06-16 Ernst-Günter Prof. Dr. Dr. Afting Pharmaceutical compositions comprising D-galactose and the use thereof
WO1999066918A1 (en) * 1998-06-23 1999-12-29 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20020193335A1 (en) * 2001-03-02 2002-12-19 Hesson David P. Gene therapy for neurological tissues
US20040127413A1 (en) * 2001-03-29 2004-07-01 Thierry Plouvier Enteric keto acid and amino acid salts and their use for preparing medicines
WO2005039539A1 (en) * 2003-10-23 2005-05-06 Medical Research Institute ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE α-KETOGLUTARATE
NZ530554A (en) * 2004-01-13 2004-04-30 A Neuronutrients

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIDGES, R. J. ET AL: "Gliotoxic actions of excitatory amino acids", NEUROPHARMACOLOGY , 31(9), 899-907 CODEN: NEPHBW; ISSN: 0028-3908, 1992, XP008061539 *
COOPER, ARTHUR J. L. ET AL: "Normal glutamate metabolism in Alzheimer 's disease fibroblasts deficient in .alpha.-ketoglutarate dehydrogenase complex activity", DEVELOPMENTAL NEUROSCIENCE (BASEL) , 18(5-6, BRAIN ENERGY METABOLISM: MOLECULES TO MAN), 499-504 CODEN: DENED7; ISSN: 0378-5866, 1996, XP008061542 *
DATABASE WPI Section Ch Week 200469, Derwent World Patents Index; Class B05, AN 2004-706724, XP002372431 *
LOSKE C ET AL: "CYTOTOXICITY OF ADVANCED GLYCATION ENDPRODUCTS IS MEDIATED BY OXIDATIVE STRESS", JOURNAL OF NEURAL TRANSMISSION, SPRINGER VERLAG, VIENNA, AT, vol. 105, no. 8/9, 1998, pages 1005 - 1115, XP000858711, ISSN: 0300-9564 *

Also Published As

Publication number Publication date
PL369552A1 (en) 2006-02-20
WO2006016828A8 (en) 2007-07-19
WO2006016828A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2006016828A8 (en) Use of alpha ketoglutarate for treating alzheimer, parkinson
SG179120A1 (en) Novel compounds
MX2009000333A (en) Pyrrolopyrimidines for pharmaceutical compositions.
IN2006KO01346A (en)
EP1032403A4 (en) Nutritional supplement for cerebral metabolic insufficiencies
MX2008012479A (en) Treatment of neurodegenerative diseases.
WO2008046810A3 (en) Alleles of the rel gene of coryneform bacteria
MY146238A (en) Prodrugs of excitatory amino acids
MY142029A (en) Phenoxyacetic acid derivatives
EP1951729A4 (en) Oxygen linked pyrimidine derivatives
MX2021009868A (en) Novel pyrido[3,4-d]pyrimidin-8-one derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, alleviating, or treating cancer, comprising same.
WO2019133770A3 (en) Glycolate oxidase inhibitors for the treatment of disease
TW200643020A (en) Crystalline form of a quinolinone-carboxamide compound
MY138708A (en) Biaryloxymethylarenecarboxylic acids
EP3949973A3 (en) Compositions and methods for treating depression
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
MX2020005866A (en) Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor.
MX2008002487A (en) Use of dextrin in animal feeds.
Zhao et al. Correlation of nitric oxide produced by an inducible nitric oxide synthase-like protein with enhanced expression of the phenylpropanoid pathway in Inonotus obliquus cocultured with Phellinus morii
MX2018009189A (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof.
MX2009003406A (en) Use of particular antibacterial compounds, which are derived from alliaceae, as natural additives in animal feed.
Yamamoto et al. Desensitization by different strategies of epidermal growth factor receptor and ErbB4
WO2020197059A3 (en) Method for inducing differentiation of stem cells into cartilage cells, using folic acid, folic acid derivative, or folic acid inhibitor
WO2005077332A3 (en) Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
EP4090736A4 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase